SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
  • 2
    Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol. 1985;29:810-816.
  • 3
    Farrow GM. Urine cytology in the detection of bladder cancer: a critical approach. J Occup Med. 1990;32:817-821.
  • 4
    Maier U, Simak R, Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol. 1995;48:314-317.
  • 5
    Sarosdy MF, Hudson MA, Ellis WJ, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 1997;50:349-353.
  • 6
    Halling KC, Kipp BR. Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol. 2007;38:1137-1144.
  • 7
    Sullivan PS, Nooraie F, Sanchez H, et al. Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a “split-sample” study. Cancer. 2009;117:167-173.
  • 8
    Sullivan PS, Chan JB, Levin MR, Rao J. Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res. 2010;2:412-440.
  • 9
    Moatamed NA, Apple SK, Bennett CJ, et al. Exclusion of the uniform tetraploid cells significantly improves specificity of the urine fish assay. Diagn Cytopathol. 2011; doi: 10.1002/dc.21831.
  • 10
    Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999;5:2121-2132.
  • 11
    Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316-323.
  • 12
    Massague J. G1 cell-cycle control and cancer. Nature. 2004;432:298-306.
  • 13
    Kong CS, Beck AH, Longacre TA. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2010;34:915-926.
  • 14
    Siddiqui MT, Hornaman K, Cohen C, Nassar A. ProEx C immunocytochemistry and high-risk human papillomavirus DNA testing in papanicolaou tests with atypical squamous cell (ASC-US) cytology: correlation study with histologic biopsy. Arch Pathol Lab Med. 2008;132:1648-1652.
  • 15
    Tambouret RH, Misdraji J, Wilbur DC. Longitudinal clinical evaluation of a novel antibody cocktail for detection of high-grade squamous intraepithelial lesions on cervical cytology specimens. Arch Pathol Lab Med. 2008;132:918-925.
  • 16
    Badr RE, Walts AE, Chung F, Bose S. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol. 2008;32:899-906.
  • 17
    Chen H, Gonzalez JL, Brennick JB, Liu M, Yan S. Immunohistochemical patterns of ProEx C in vulvar squamous lesions: detection of overexpression of MCM2 and TOP2A. Am J Surg Pathol. 2010;34:1250-1257.
  • 18
    David O, Cabay RJ, Pasha S, et al. The role of deeper levels and ancillary studies (p16(Ink4a) and ProExC) in reducing the discordance rate of Papanicolaou findings of high-grade squamous intraepithelial lesion and follow-up cervical biopsies. Cancer. 2009;117:157-166.
  • 19
    Guo M, Baruch AC, Silva EG, et al. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol. 2011;135:212-220.
  • 20
    Pinto AP, Schlecht NF, Woo TY, Crum CP, Cibas ES. Biomarker (ProEx C, p16(INK4A), and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol. 2008;21:1067-1074.
  • 21
    Sanati S, Huettner P, Ylagan LR. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol. 2010;29:79-87.
  • 22
    Walts AE, Bose S. p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol. 2009;40:957-964.
  • 23
    Walts AE, Bose S. BD ProEx C immunostaining in extramammary Paget's disease and perineal melanoma. Mod Pathol. 2009;22:246-251.
  • 24
    Howanitz JH, Howanitz PJ. Principles of laboratory medicine. In: Howanitz JH, Howanitz PJ, editors. Laboratory Medicine: Test Selection and Interpretation. 1st ed. New York: Churchill Livingston; 1991:1-10.
  • 25
    StatSoft I. Statistica (data analysis software system), version 9. Tulsa, OK: StatSoft; 2009. www.statsoft.com.
  • 26
    Foot NC, Papanicolaou GN. Early renal carcinoma in situ detected by means of smears of fixed urinary sediment. J Am Med Assoc. 1949;139:356-358.
  • 27
    Presti JC, Weyrauch HM. Papanicolaou examination of urine in diagnosis of urinary cancer. I. As a test in mass screening. Trans West Sect Am Urol Assoc. 1954;21:150-154.
  • 28
    Presti JC, Weyrauch HM. Papanicolaou examination of urine in diagnosis of urinary cancer. I. As a test in mass screening. J Urol. 1955;73:430-434.
  • 29
    Weyrauch HM, Presti JC. Papanicolaou examination of urine in diagnosis of urinary cancer. II. False positives in diagnosis of renal neoplasms. Trans Am Assoc Genitourin Surg. 1955;47:198-204.
  • 30
    Weyrauch HM, Presti JC. Papanicolaou examination of urine in diagnosis of urinary cancer. II. False positives in diagnosis of renal neoplasms. J Urol. 1956;75:551-557.
  • 31
    Foot NC, Papanicolaou GN, Holmquist ND, Seybolt JF. Exfoliative cytology of urinary sediments; a review of 2,829 cases. Cancer. 1958;11:127-137.
  • 32
    Khalbuss W, Goodison S. Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology. Cytojournal. 2006;3:18.
  • 33
    Iczkowski KA, Katz G, Cascione CJ. Postoperative bladder washing cytology after transurethral resection. Can it predict the recurrence of urothelial carcinoma? Acta Cytol. 2004;48:380-384.
  • 34
    Srivastava R, Arora VK, Aggarwal S, Bhatia A, Singh N, Agrawal V. Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma. Diagn Cytopathol. 2012;40:755-759.
  • 35
    Klein A, Zemer R, Buchumensky V, Klaper R, Nissenkorn I. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer. 1998;82:349-354.
  • 36
    Lin S, Hirschowitz SL, Williams C, Shintako P, Said J, Rao JY. Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: preliminary retrospective study on archived urine slides. Cancer Detect Prev. 2001;25:202-209.
  • 37
    Cheng L, Reiter RE, Jin Y, et al. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. JUrol. 2003;169:2094-2100.
  • 38
    Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol. 1999;161:62-65.
  • 39
    Nguyen CT, Jones JS. Defining the role of NMP22 in bladder cancer surveillance. World J Urol. 2008;26:51-58.
  • 40
    Ponsky LE, Sharma S, Pandrangi L, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol. 2001;166:75-78.
  • 41
    Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999;162:53-57.
  • 42
    Toma MI, Friedrich MG, Hautmann SH, et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol. 2004;22:145-149.
  • 43
    Hautmann S, Toma M, Lorenzo Gomez MF, et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol. 2004;46:466-471.
  • 44
    Burger M, Denzinger S, Hartmann A, Wieland WF, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer. 2007;96:1711-1715.